IKIris Kventsel

Iris Kventsel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iris Kventsel has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rate of germline pathogenic sequence variants in cancer susceptibility genes in an Israeli pediatric and adolescent cancer cohort: a single institute experience

    by Dana Nahom, Zehavit Frenkel, Amos Toren, Eitan Friedman, Iris Kventsel

    Multi-cancer predisposition gene panel testing (MCPGT) enables simultaneous deep-coverage genotyping of multiple CPGs (cancer predisposing genes) and detects germline pathogenic sequence variants (PSVs). Reported PSV carrier rates among pediatric and adolescent cancer patients range from 8 to 17.6%, with variability attributed to ethnic background, the number of genes tested, cancer phenotypes, and patient selection criteria. This study aimed to assess the rate and spectrum of germline PSVs in consecutive pediatric and adolescent cancer patients treated at the Sheba Medical Center, a tertiary medical center. All cancer patients aged 0–18 years treated between 01.2021 and 12.2022 were offered MCPGT. Overall, 257 eligible cancer patients were treated during the study period, of whom 116 Israeli patients underwent MCGPT (Invitae, San Francisco, CA), with complete data available for 108. The range of malignancies included central nervous system (CNS) tumors (n = 45), solid tumors (n = 37), hematological malignancies (n = 14), and retinoblastoma (RB) (n = 12). PSVs were detected in 17/108—15.7% of patients, with the highest rates in patients with RB (7/12, 58.3%) and CNS tumors (6/45, 13.3%). A significant association was found between younger age at diagnosis and PSV carrier status (4.7 years in carriers vs. 9.3 years in non-carriers, p = 0.003). Fulfilling Jongmans' criteria was correlated with PSV detection. The study highlights the importance of genetic testing in children meeting specific clinical criteria, particularly those diagnosed with RB and CNS tumors. Further studies with larger, ethnically diverse cohorts are needed to validate these findings to expand the scientific basis for personalized care strategies.


  • Open Access

    AB003. Circulating EBV (cEBV) and metabolic imaging monitoring during therapy for thymic lymphoepithelioma-like carcinoma (tLELC): a case study

    by Haim Biran, Iris Kventsel, Gadi Abebe-Campino, Efrat Ofek, M Teperberg, Iris Eshed, Amos Simon, Edith M. Marom

    EBV association with the rare and usually fatal tLELC has been well documented, but not thoroughly studied, in the literature. A symptomatic 16-year-old boy was admitted for a locally advanced, inoperable EBV-associated tLELC. The diagnosis was established by appropriate immunohistology and RNA in-situ hybridization (ISH) for EBNA. The patient responded to induction combination chemotherapy followed by consolidation irradiation course given to the primary mediastinal lesion. Later, upon disease progression, he was enrolled to an immunotherapy (pembrolizumab) phase II clinical trial. Under this therapy, disease control was regained and lasted about 8 months. Treatment was discontinued, due to disease progression, after completion of 13 courses. Disease evaluation included serial circulating plasma EBV titer as well as concomitant 18F-FDG PET-CT scintigraphy/scanning. We attempt herein to compare how well the four different measurement modalities employed, namely-RECIST 1.1., active FDG-avid tumor volume, SUVmax and cEBV reflect the clinical course of disease and tumor burden changes. Among these, FDG-avid tumor volume apparently conforms better than conventional bi-dimentional CT-based RECIST 1.1 to the actual tumor burden and clinical course. Similarly, cEBV titer seems sensitive to various therapeutic intervention including irradiation. Furthermore, being a subclinical sensor, it could provide lead-time and herald overt disease progression. Albeit the entity presented, namely EBV-associated tLELC is extremely rare, certain conclusions obtained could, when properly modified, be applied in the management of more common conditions.

  • Open Access

    Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group

    by M. C. Frühwald, K. Nemes, H. Boztug, M. C. A. Cornips, D. G. Evans, R. Farah, S. Glentis, M. Jorgensen, K. Katsibardi, S. Hirsch, et al.

    The rhabdoid tumor (RT) predisposition syndromes 1 and 2 (RTPS1 and 2) are rare genetic conditions rendering young children vulnerable to an increased risk of RT, malignant neoplasms affecting the kidney, miscellaneous soft-part tissues, the liver and the central nervous system (Atypical Teratoid Rhabdoid Tumors, ATRT). Both, RTPS1&2 are due to pathogenic variants (PV) in genes encoding constituents of the BAF chromatin remodeling complex, i.e. SMARCB1 (RTPS1) and SMARCA4 (RTPS2). In contrast to other genetic disorders related to PVs in SMARCB1 and SMARCA4 such as Coffin-Siris Syndrome, RTPS1&2 are characterized by a predominance of truncating PVs, terminating transcription thus explaining a specific cancer risk. The penetrance of RTPS1 early in life is high and associated with a poor survival. However, few unaffected carriers may be encountered. Beyond RT, the tumor spectrum may be larger than initially suspected, and cancer surveillance offered to unaffected carriers (siblings or parents) and long-term survivors of RT is still a matter of discussion. RTPS2 exposes female carriers to an ill-defined risk of small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT), which may appear in prepubertal females. RT surveillance protocols for these rare families have not been established. To address unresolved issues in the care of individuals with RTPS and to propose appropriate surveillance guidelines in childhood, the SIOPe Host Genome working group invited pediatric oncologists and geneticists to contribute to an expert meeting. The current manuscript summarizes conclusions of the panel discussion, including consented statements as well as non-evidence-based proposals for validation in the future.